Celladon Corporation (CLDN) Downtrend Brings Out Bears

Traders are on edge ahead of trial results from Celladon Corporation (CLDN)

by

Published on Apr 20, 2015 at 2:38 PM
Updated on Apr 21, 2015 at 9:38 AM

Celladon Corporation (NASDAQ:CLDN) is among a number of health care stocks getting whacked today -- down 4% at $15.86 ahead of crucial results from its Mydicar gene therapy trial, due out sometime this month. In the equity's options pits, puts are running at more than twice their usual intraday rate. Also, CLDN's 30-day at-the-money implied volatility earlier touched an annual high of 418.6%, hinting at heightened anxiety levels ahead of the aforementioned data.

The most active put this afternoon is the May 17.50 strike, where likely buy-to-open activity is transpiring. Based on the volume-weighted average price (VWAP) of $7.97, the buyers are aiming for CLDN to plummet below $9.53 (strike less VWAP) by May options expiration. This would put the stock in waters not charted since mid-October.

Today's penchant for put buying is par for the course. During the past 10 days across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), CLDN has racked up a put/call volume ratio of 3.43 -- with puts bought to open at more than three times the rate of calls.

Short sellers have been extremely active of late, too. During the two most recent reporting periods, short interest on CLDN nearly tripled, and now makes up 23% of its total float -- though it would take less than two days to cover these positions, at average daily trading levels.

On the charts, Celladon Corporation's (NASDAQ:CLDN) intraday losses are pretty typical. Since notching a record high of $28.25 on March 20, the stock has plunged an astounding 44%, and underperformed the broader S&P 500 Index (SPX) by about 36 percentage points.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
Silver Lining for Struggling Ulta Beauty Stock
Historically, ULTA is one of the best stocks to own in the second quarter
3M Ramps Up Face Mask Production on White House Order, Stock Slips
President Trump said he would invoked the Defense Production Act against 3M in a tweet late on Thursday
Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.